Visum Therapeutics Company
%20.jpg)
Visum Therapeutics develops small molecule y p p g therapeutic to treat Stargardt's disease, a degenerative condition that leads to blindness and is the most common form of inherited juvenile macular degeneration. Much of the pathology of Stargardt's disease is shared with the more common Age-related Macular Degeneration (AMD).
Headquarters:
Cleveland, Ohio, United States
Funding Status:
Seed
Technology:
P4 Medicine
Investor Type:
For Profit
Founded Date:
1-1
Industry:
Biotechnology, Health Diagnostics, Life Science, Therapeutics